Article
Biological challenges of BRAF inhibitor therapy.
Molecular oncology - 1 Apr 2011
Puzanov Igor, Burnett Patrick, Flaherty Keith T
Abstract excerpt
Activating mutations in BRAF, a constituent of the map kinase pathway, were first discovered as being most prevalent in melanoma in 2002. Only recently have potent and selective, orally available inhibitors of BRAF emerged for clinical testing and demonstrated clear evidence of tumor regression in the majority of patients whose tumors harbor a BRAF mutation. While these early observations suggest that the BRAF...
Topics
- Animals
- Antineoplastic Agents
- Humans
- MAP Kinase Signaling System
- Melanoma
- Mutation
- Protein Kinase Inhibitors
- Proto-Oncogene Proteins B-raf